New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses1Data from MajesTEC-1 study published in The New England Journal of Medicine2BEERSE, Belgium (B.
/PRNewswire/ A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled.
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients
Ciltacabtagene autoleucel (cilta-cel), Janssen's first cell therapy, is a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies The Janssen Pharmaceutical Companies of Johnson
National Institute for Health and Care Excellence says ‘yes’ to Darzalex®▼ (daratumumab) for relapsed and refractory multiple myeloma High Wycombe, 15th March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson welcomes the decision by the National Institute for Health and.